[Corrections] Correction to Lancet Infect Dis 2026; published online Jan 28. https://doi.org/10.1016/S1473-3099(25)00747-9
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00120-9/fulltext?rss=yes
Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis 2026; published online Jan 28. https://doi/org/10.1016/S1473-3099(25)00747-9—In this Article, the p value in the Findings in the Summary for patients with microbiologically confirmed tuberculosis in the diagnosis-dependent high-dose group compared with the diagnosis-dependent conventional-dose group should have been 0·079.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00120-9/fulltext?rss=yes
Heysell SK, Mpagama SG, Nuwagira E, et al. Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 × 2 factorial, superiority trial. Lancet Infect Dis 2026; published online Jan 28. https://doi/org/10.1016/S1473-3099(25)00747-9—In this Article, the p value in the Findings in the Summary for patients with microbiologically confirmed tuberculosis in the diagnosis-dependent high-dose group compared with the diagnosis-dependent conventional-dose group should have been 0·079.
[Profile] Katharina Kranzer—led by curiosity, committed to capacity
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00127-1/fulltext?rss=yes
Katharina Kranzer has always wanted to understand how things work. As a child moving between the USA, Austria, and Germany due to her father's work as a physicist, she developed early a habit of examining systems from the outside. She briefly considered studying history and politics, but her mother helped convince her medicine offered something more tangible: a way to interrogate the world and change it. At the Technical University of Munich, Germany, where she chose to study in part to be close to the mountains she loved, it was not the routine of clinical training that captivated her.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00127-1/fulltext?rss=yes
Katharina Kranzer has always wanted to understand how things work. As a child moving between the USA, Austria, and Germany due to her father's work as a physicist, she developed early a habit of examining systems from the outside. She briefly considered studying history and politics, but her mother helped convince her medicine offered something more tangible: a way to interrogate the world and change it. At the Technical University of Munich, Germany, where she chose to study in part to be close to the mountains she loved, it was not the routine of clinical training that captivated her.
[Editorial] GoGoVax dispels hopes for gonorrhoea vaccination
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00126-X/fulltext?rss=yes
In 2020, WHO estimated that there were 82·4 million new infections with Neisseria gonorrhoeae among adults aged 15–49 years and up to 2022, the incidence of gonorrhoea had been on the rise globally for a decade. While in the last three years a decrease in the number of cases has been observed in several countries, including the USA and the UK, with antimicrobial resistance constituting a major barrier to treatment and no gonorrhoea vaccine available, protecting populations at risk from the disease remains a challenge.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00126-X/fulltext?rss=yes
In 2020, WHO estimated that there were 82·4 million new infections with Neisseria gonorrhoeae among adults aged 15–49 years and up to 2022, the incidence of gonorrhoea had been on the rise globally for a decade. While in the last three years a decrease in the number of cases has been observed in several countries, including the USA and the UK, with antimicrobial resistance constituting a major barrier to treatment and no gonorrhoea vaccine available, protecting populations at risk from the disease remains a challenge.
👍1
[Corrections] Correction to Lancet Infect Dis 2026; 26: 343–61
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00124-6/fulltext?rss=yes
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis 2026; 26: 343–61—In the Declaration of interests section of this Article, the statement has been corrected for Bogdan Oancea. This correction has been made to the online version as of March 25, 2026, and the printed version is correct.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00124-6/fulltext?rss=yes
GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators. Global burden of lower respiratory infections and aetiologies, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Infect Dis 2026; 26: 343–61—In the Declaration of interests section of this Article, the statement has been corrected for Bogdan Oancea. This correction has been made to the online version as of March 25, 2026, and the printed version is correct.
❤1
[Newsdesk] Research in brief
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00129-5/fulltext?rss=yes
A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00129-5/fulltext?rss=yes
A phase 2 randomised trial compared a full or half dose of a live-attenuated chikungunya vaccine (VLA1553) versus an active control (meningococcal vaccine) in 304 children aged 1–11 years in Honduras and the Dominican Republic. Up to 14 days after vaccination, there were no significant between-group differences in incidence or severity of solicited adverse events (AEs). The most common unsolicited AEs through 28 days after vaccination were infections and infestations, occurring in 10·0–20·5% of participants.
❤3👍1
Enhanced Detection of Coccidioides spp. Fungi from Environmental Samples Using Droplet Digital PCR
https://wwwnc.cdc.gov/eid/article/32/4/25-1146_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1146_article
Emerging Infectious Diseases journal
Enhanced Detection of <em>Coccidioides</em> spp. Fungi from Environmental Samples Using Droplet Digital PCR
Detection of <em>Coccidioides</em> spp. Fungi Using ddPCR
Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance
https://wwwnc.cdc.gov/eid/article/32/4/25-1906_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1906_article
Emerging Infectious Diseases journal
Confirming ERVEBO Vaccination to Support Ebola Virus Surveillance
ERVEBO Vaccination to Support Ebola Surveillance
Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus Infection in Humans and Domestic Ruminants, Democratic Republic of the Congo
https://wwwnc.cdc.gov/eid/article/32/4/25-0969_article
https://wwwnc.cdc.gov/eid/article/32/4/25-0969_article
Emerging Infectious Diseases journal
Seroprevalence of Crimean-Congo Hemorrhagic Fever Virus Infection in Humans and Domestic Ruminants, Democratic Republic of the…
Who is this person and what did she accomplish?
https://wwwnc.cdc.gov/eid/article/32/4/25-1083_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1083_article
Emerging Infectious Diseases journal
Who is this person and what did she accomplish?
Photo Quiz
Anopheles stephensi [ә-nah′-fuhl-ēz ste′-fen-zī]
https://wwwnc.cdc.gov/eid/article/32/4/24-1933_article
https://wwwnc.cdc.gov/eid/article/32/4/24-1933_article
Emerging Infectious Diseases journal
<em>Anopheles stephensi</em> [ә-nah′-fuhl-ēz ste′-fen-zī]
Geographically Distinct Circulation of Genotype II and III St. Louis Encephalitis Virus, Texas, USA, 2009–2024
https://wwwnc.cdc.gov/eid/article/32/4/25-0934_article
https://wwwnc.cdc.gov/eid/article/32/4/25-0934_article
Emerging Infectious Diseases journal
Geographically Distinct Circulation of Genotype II and III St. Louis Encephalitis Virus, Texas, USA, 2009–2024
Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023–2024
https://wwwnc.cdc.gov/eid/article/32/4/25-1711_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1711_article
Emerging Infectious Diseases journal
Border Region Surveillance of Malaria Drug Resistance, Northern Burundi, 2023–2024
Malaria Drug Resistance, Burundi, 2023–2024
Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA
https://wwwnc.cdc.gov/eid/article/32/4/25-1206_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1206_article
Emerging Infectious Diseases journal
Evaluation of Effectiveness of Autocidal Gravid Ovitraps for Preventing Zika Virus Infection, Puerto Rico, USA
Gravid Ovitraps for Preventing ZIKV Infection
Tropism and Replication Competence of Cattle Influenza A(H5N1) Genotype B3.13 Virus in Human Bronchus and Lung Tissue
https://wwwnc.cdc.gov/eid/article/32/5/25-1926_article
https://wwwnc.cdc.gov/eid/article/32/5/25-1926_article
Emerging Infectious Diseases journal
Tropism and Replication Competence of Cattle Influenza A(H5N1) Genotype B3.13 Virus in Human Bronchus and Lung Tissue
Influenza A(H5N1) B3.13 in Human Tissue
❤1
[Comment] Structural stigma: an urgent intervention priority in Africa
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00359-5/fulltext?rss=yes
Improved access to antiretroviral therapy (ART) for people with HIV has greatly affected the trajectory of the global HIV pandemic, enabling people with HIV to lead long, healthy lives and curtailing the number of people who newly acquire HIV. Between 2000 and 2024, the number of people with HIV accessing ART globally increased from 370 000 to 31·6 million.1 Over the same period, the percentage of people with HIV accessing ART increased from 0% to 83% in Africa,2 a region that accounts for nearly two-thirds of the 40·8 million people with HIV worldwide.
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00359-5/fulltext?rss=yes
Improved access to antiretroviral therapy (ART) for people with HIV has greatly affected the trajectory of the global HIV pandemic, enabling people with HIV to lead long, healthy lives and curtailing the number of people who newly acquire HIV. Between 2000 and 2024, the number of people with HIV accessing ART globally increased from 370 000 to 31·6 million.1 Over the same period, the percentage of people with HIV accessing ART increased from 0% to 83% in Africa,2 a region that accounts for nearly two-thirds of the 40·8 million people with HIV worldwide.
Accelerated Increase in Candida auris Bloodstream Infections during COVID-19 Pandemic, South Africa
https://wwwnc.cdc.gov/eid/article/32/4/25-1407_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1407_article
Emerging Infectious Diseases journal
Accelerated Increase in <em>Candida auris</em> Bloodstream Infections during COVID-19 Pandemic, South Africa
<em>C. auris</em> Infections during COVID-19 Pandemic
❤2
Ecologic Investigative Strategies to Determine Human Plague Exposure Sites, United States, 1991–2018
https://wwwnc.cdc.gov/eid/article/32/4/25-1357_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1357_article
Emerging Infectious Diseases journal
Ecologic Investigative Strategies to Determine Human Plague Exposure Sites, United States, 1991–2018
Strategies to Determine Plague Exposure Sites, USA
Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016–2021
https://wwwnc.cdc.gov/eid/article/32/4/25-0942_article
https://wwwnc.cdc.gov/eid/article/32/4/25-0942_article
Emerging Infectious Diseases journal
Dengue Incidence, Seroprevalence, and Expansion Factors from Active Surveillance, Brazil, 2016–2021
Dengue Active Surveillance, Brazil, 2016–2021
Investigation of and Response to Autochthonous Dengue, Los Angeles County, California, USA, August–November 2024
https://wwwnc.cdc.gov/eid/article/32/5/25-1812_article
https://wwwnc.cdc.gov/eid/article/32/5/25-1812_article
Emerging Infectious Diseases journal
Investigation of and Response to Autochthonous Dengue, Los Angeles County, California, USA, August–November 2024
Autochthonous Dengue, California, USA
Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014–2024
https://wwwnc.cdc.gov/eid/article/32/4/25-1022_article
https://wwwnc.cdc.gov/eid/article/32/4/25-1022_article
Emerging Infectious Diseases journal
Circulation Patterns, Genetic Diversity, and Public Health Implications of Enterovirus D68, Europe, 2014–2024
Enterovirus D68 Circulation, Europe, 2014–2024